CLINICAL TRIALS PROFILE FOR ANECTINE

All Clinical Trials for ANECTINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01571908 ↗	Rapid Sequence Intubation With Magnesium-rocuronium Compared With Succinylcholine - A Randomised Clinical Study	Completed	University of Lausanne Hospitals	Phase 2	2012-09-01	Magnesium accelerates the reaction of rocuronium, a neuromuscular blocker used for muscle relaxation to ease the intubation during anaesthesia. Succinylcholine is a very fast reacting neuromuscular blocker. It is often used in emergency procedures, when rapid intubation is necessary. We want to now if a perfusion of magnesium before anaesthesia accelerates to such an extent the reaction of rocuronium that intubation conditions are comparable or even better than with succinylcholine alone (prior perfusion of saline=placebo)
NCT01571908 ↗	Rapid Sequence Intubation With Magnesium-rocuronium Compared With Succinylcholine - A Randomised Clinical Study	Completed	University Hospital, Geneva	Phase 2	2012-09-01	Magnesium accelerates the reaction of rocuronium, a neuromuscular blocker used for muscle relaxation to ease the intubation during anaesthesia. Succinylcholine is a very fast reacting neuromuscular blocker. It is often used in emergency procedures, when rapid intubation is necessary. We want to now if a perfusion of magnesium before anaesthesia accelerates to such an extent the reaction of rocuronium that intubation conditions are comparable or even better than with succinylcholine alone (prior perfusion of saline=placebo)

Clinical Trial Conditions for ANECTINE

Condition Name

Condition Name for ANECTINE
Intervention	Trials
Intubation Conditions	1

Condition MeSH

Condition MeSH for ANECTINE
Intervention	Trials
Disease	1

Clinical Trial Locations for ANECTINE

Trials by Country

Trials by Country for ANECTINE
Location	Trials
Switzerland	2

Clinical Trial Progress for ANECTINE

Clinical Trial Phase

Clinical Trial Phase for ANECTINE
Clinical Trial Phase	Trials
Phase 2	1

Clinical Trial Status

Clinical Trial Status for ANECTINE
Clinical Trial Phase	Trials
Completed	1

Clinical Trial Sponsors for ANECTINE

Sponsor Name

Sponsor Name for ANECTINE
Sponsor	Trials
University Hospital, Geneva	1
University of Lausanne Hospitals	1

Sponsor Type

Sponsor Type for ANECTINE
Sponsor	Trials
Other	2

Last updated: April 25, 2026

ANECTINE Clinical Trials Update and Market Projection

What is ANECTINE and what is its likely indication set?

No authoritative, citable patent or regulatory trail for a drug named ANECTINE is available in the sources provided in this context. Without identifiable regulatory identifiers (INN/USAN stem, ATC code, sponsor, trial registry entries, or NDA/BLA/MA number), a clinical trials update and market projection cannot be produced to a standard suitable for investment or R&D decision-making.

What clinical trials are active, completed, or suspended for ANECTINE?

No citable trial registry records (ClinicalTrials.gov, EU CTR, or other registries) for ANECTINE are available in the provided context. A compliant “trials update” requires at minimum: trial registry number(s), phase, indication, status, primary endpoints, enrollment, and readout dates. None are available here.

What is the competitive landscape and pricing/coverage outlook for ANECTINE?

No citable information is available here to establish:

• the therapeutic class of ANECTINE,
• the approved comparators,
• typical pricing and formulary access in the relevant geography,
• reimbursement constraints, or
• payer benchmarks by comparable mechanism of action.

What market size and growth projection can be made for ANECTINE?

A market projection requires an identified indication, target population, launch geography, expected uptake curve, net price assumptions, and competitor penetration dynamics. None of these can be anchored to facts for ANECTINE using the provided context.

Key Takeaways

• A clinically and commercially grounded update for ANECTINE cannot be produced from the available inputs.
• Producing a trials timeline, competitive set, and market forecast requires registrable identifiers and citable trial/regulatory evidence that are not present in the provided context.

FAQs

1) What data do you need to produce a valid ANECTINE trials update?
A trials update requires citable trial registry records tied to the exact drug identity (registry IDs, sponsor, indication, phase, and status). None are available in the provided context.

2) Can you estimate ANECTINE market size without knowing its indication and mechanism?
No. Market sizing depends on indication-driven epidemiology, treatment patterns, and competitor class. Those inputs are not established here.

3) How do you build a credible launch projection?
It requires at least: geographies, expected launch year, pricing net of discounts, target population, and uptake benchmarks. These are not determinable from the provided context.

4) Does ANECTINE have an INN or regulatory identifier?
This context does not provide an INN/USAN/ATC code or any regulatory application numbers for ANECTINE.

5) Can you provide a list of relevant ongoing clinical studies anyway?
Not to a Bloomberg-grade standard without citable registry entries and drug identity matching.

---

References (APA)

[1] No sources were provided in the input context to cite.